The Antidote: Inside the World of New Pharma (71 page)

(
pp. 255
–58) Interviews with Jack Weet, Bob Kauffman, and Matt Emmens.

(
pp. 258
–61) Interview with Matt Emmens.

(
pp. 261
–63) Interviews with Matt Emmens, Ann Kwong, Ian Smith, and Michael Partridge. Naomi Kresge, “Pharmasset to Challenge Vertex Hepatitis C Treatment, BMO Says,”
Bloomberg
, March 8, 2011; Adam Feuerstein, “Pharmasset Hep C Data Wows Investors,” TheStreet, March 8, 2011; Robert Weinstein, “Pharmasset: The Real Numbers Behind the Hype,”
Seeking Alpha
, March 11, 2011; Katan Desai, “Who Will Win the Hepatitis C Market?”
Seeking Alpha
, March 14, 2011; Adam Feuerstein, “Hep C Drug Stocks in the Spotlight,” TheStreet, March 28, 2011; NBC Evening News, March 30, 2011.

I was in attendance at all scenes described in chapters 11 to 14 unless otherwise specified. Additional sources:

(
pp. 264
–68) Interviews with Bob Kauffman, Josh Boger, Camilla Graham, Amit Sachdev, Nancy Wysenski, and Jack Weet. Emily P. Walker, “FDA Panel Endorses Boceprevir for Hepatitis C,”
medpagetoday.com
, April 27, 2011; Heidi Ledford, “Regulatory Advisors Recommend New Hepatitis C Drug,”
nature.com
, April 28, 2011.

(
pp. 268
–73) Interviews with Nancy Wysenski, Jack Weet, Megan Pace, Bob Kauffman, and Matt Emmens. “Noteworthy Pharmacist, Patrick Clay, Pharm.D.,”
TheBody.com
, HIV Leadership Awards 2005; on Clay’s research funding from Merck,
American Journal of Pharmaceutical Education
, 65 (Winter 2001), p. 426.

(
pp. 273
–77) Interviews with Peter Mueller, Jack Weet, and Bob Kauffman. Jason Brudereck, “New Drug Has City Woman Free of Hepatitis C,”
Reading (Pa.) Eagle
, June 1, 2011; Luke Timmerman, “Vertex Wins FDA Panel’s Recommendation for New Hepatitis C Drug,” Xconomy, April 28, 2011; Robert Weissman, “Hepatitis C Drug from Vertex Sails Through Test,”
Boston Globe
, April 29, 2011; Richard Knox, “New Drugs for Hepatitis C Called Game Changers,”
NPR.org
, April 28, 2011; “Vertex Hepatitis Drug Still Holds Edge on Merck After FDA Panels,”
Wall Street Journal
, April 29, 2011; Brian Orelli, “Coronations for New Drug Royalty,”
The Motley Fool/
Fool.com
, April 2011; “Goldman Sachs Raises Price Target on Vertex (VRTX), Sees 100% Chance of Approval Now,”
StreetInsider.com
, April 29, 2011.

(
pp. 277
–80) Interviews with Bo Cumbo and Ken Boger.

(
pp. 280
–83) Interviews with Ian Smith and Matt Emmens.

(
pp. 283
–85) Interviews with Bo Cumbo, Matt Emmens, and Nancy Wysenski. Luke Timmerman, “Merck, Genentech Team Up on Hepatitis C Drugs, Raising Ante in Vertex Rivalry,” Xconomy, May 17, 2011; Brian Orelli, “If You Can’t Beat ’Em, Use ’Em to Beat Your New Rival,”
The Motley Fool/
Fool.com
, May 18, 2011; Tracy Staton, “Can Merck/Roche Hep C Deal Put Victrelis on Top?” FiercePharma, May 18, 2011; “Merck and Co.: HCV Marketing Juggernaut,”
UBS Investment Research
, May 17, 2011; Linda A. Johnson, “Merck, Roche Expand Hepatitis C Drug Promo Deal,”
BloombergBusinessweek
, July 20, 2011.

(
pp. 285
–88) Interviews with Nancy Wysenski, John Condon, Paul Daruwala, Josh Boger, and Adam Koppel. Matthew Herper, “Vertex’s Biggest Advantage,”
Forbes
, May 24, 2011; “Vertex’s Sales Force Gears Up for ‘David vs. Goliath’ Marketing Push,”
Wall Street Journal
, May 24, 2011; Bill Berkrot and Lewis Krauskopf, “Vertex CEO Unfazed by Competition, Future Rivals,” Reuters, May 25, 2011.

(
pp. 288
–91) Interview with John Thomson.

(
pp. 291
–94) Interviews with Matt Emmens and Josh Boger.

(
pp. 295
–99) Interviews with Ken Boger, Ian Smith, Peter Mueller, and Geoff Porges. Thomas Gryta, “Vertex Reports Positive Test of Cystic Fibrosis Combo,”
Wall Street Journal
, June 9, 2011; “Vertex Cystic Fibrosis Combo Shows Promise,” Reuters, June 9, 2011; Adam Feuerstein, “Vertex Cystic Fibrosis Drug Combo Hits Bump,” TheStreet June 9, 2011; Marley Seaman, “Vertex Falls on Cystic Fibrosis Study Data,”
Forbes
, June 9, 2011; Geoff Meacham, “Vertex Pharmaceuticals: Our Thoughts Ahead of VX-809/VX-770 Combo Data in Cystic Fibrosis,”
JP Morgan North America Equity Research
, May 2, 2011.